IIBDGC >16 Collaborating Countries
Contact details of the individual groups are listed below. Please direct International IBD Genetics Consortium enquiries to firstname.lastname@example.org
The UK IBD Genetics Consortium (http://www.ibdresearch.co.uk/) is an open group consisting of a number of clinical centres and the Wellcome Sanger Institute (Analysts : Jeff Barrett and Carl Anderson). We have presently recruited over 10,000 patients with Crohn's disease and ulcerative colitis into our genetics studies. GWAS have been performed in Crohn's disease as part of the original Wellcome Trust Case Control Consortium (WTCCC) experiment and in ulcerative colitis as part of WTCCC2. Please contact UKIBDGC at UKIBDGC_enquiries@sanger.ac.uk
- Cambridge : Miles Parkes, James Lee
- Edinburgh : Jack Satsangi, Charlie Lees, Elaine Nimmo
- Exeter : Tariq Ahmad, Cathryn Edwards
- Oxford : Alison Simmons
- London : Chris Mathew, Natalie Prescott, Jeremy Sanderson, Ailsa Hart
- Newcastle: John Mansfield, Chris Lamb
- Manchester: William Newman
- Dundee: Craig Mowat
- Early-onset IBD: David Wilson
New centres for 2011 include:
- Birmingham (Rachel Cooney),
- Norwich (Mark Tremelling) and
- Nottingham (Chris Hawkey)
The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was created in 2002 by the National Institute of Diabetes, Digestive and Kidney diseases (NIDDK); to advance knowledge on the inflammatory bowel diseases, specifically Crohn's Disease and Ulcerative Colitis.
The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) consists of six genetic research centers (GRC) and a data coordinating center (DCC). The IBDGC is involved with independent genetic research studies and actively works with a variety of members from the broader IBD and genetics communities on collaborative projects.
The NIDDK IBDGC Principal Investigators are:
- Judy H. Cho, MD - Icahn School of Medicine at Mount Sinai
- Steven R. Brant, MD - Johns Hopkins University
- Richard H. Duerr, MD - University of Pittsburgh
- Dermot B. P. McGovern, MD, PhD, MRCP - Cedars Sinai Medical Center
- John D. Rioux, PhD - University of Montreal
- Mark S. Silverberg, MD, PhD, FRCPC - University of Toronto
For further information please refer to the The NIDDK Inflammatory Bowel Disease Genetics Consortium's webpage
The French UC patients have been diagnosed, recruited and followed up at the University Hospital of Lille and Nancy. The principal investigators from this group are :
- Professor Jean-Frédéric Colombel from the Hepato-Gastroenterology unit at the University Hospital of Lille (email@example.com)
- Professor Laurent Peyrin-Biroulet from the Hepato-Gastroenterology unit at the University Hospital of Lille (firstname.lastname@example.org)
- Dr Mathias Chamaillard from the Inserm email@example.com
- Mauro D'Amato, Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm
- Leif Torkvist, Department of Clinical Science Intervention and TEchnology, Karolinska Institutet, Stockholm
- Jonas Halfvarson, Department of Internal Medicine, Örebro University Hospital, Örebro
The Dutch initiative on Crohn and colitis (ICC) is a nationwide collaborative effort from all eight university medical centers in the Netherlands studying the inflammatory bowel diseases.PI ICC-Genetics: R.K.Weersma, MD PhD Gastroenterologist Department of Gastroenterology and Hepatology University Medical Center Groningen PO Box 30.001 9700RB Groningen the Netherlands T: +31503610426 F: +31503619306 firstname.lastname@example.org
Site: Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Germany & 1st Medical Department of the University Hospital S.-H., Campus Kiel
- Prof. Dr. rer. nat. Andre Franke
- Prof. Dr. med. Stefan Schreiber
- Tobias Balschun
- David Ellinghaus
Belgian IBD Genetics Consortium consists of: (alphabetical order of centres) - first name for each centre is the PI
- Brussels Erasme University (Erasme): Denis Franchimont, Andre Van Gossum, Leila Amininejad
- University of Ghent (UGent): Martine De Vos, Debby Laukens
- University of Leuven (KULeuven; www.ibd-kuleuven.com): Severine Vermeire, Paul Rutgeerts, Isabelle Cleynen
- University of Liege (ULG): Michel Georges, Edouard Louis, Emilie theatre
The Italian IBD cohort is a hospital-based population, collected in tertiary referral centers.
The member of the MC and coordinator of the Italian cohort is Vito Annese (email@example.com), Head of Gastroenterology at the University Hospital Careggi of Florence
The principal investigators (first name) and collaborators at different sites are:
- Angelo Andriulli (firstname.lastname@example.org), Fabrizio Bossa (email@example.com), Anna Latiano (firstname.lastname@example.org), Orazio Palmieri (email@example.com), Gastroenterology Department and Research Lab, IRCCS-CSS Hospital, San Giovanni Rotondo
- Renata D'Incá (firstname.lastname@example.org), Department of Gastroenterology, University of Padua
- Silvio Danese (email@example.com), Gionata Fiorino (firstname.lastname@example.org), IBD Unit, Humanitas University, Rozzano, Milan
- Salvatore Cucchiara (email@example.com), Laura Stronati (firstname.lastname@example.org), Department of Pediatrics, La Sapienza University, Rome
- Paolo Lionetti (email@example.com), Unit of Pediatric Gastroenterology, Childrens' Hospital Meyer, University of Florence
Australia and New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC)
The ANZIBDC was formed in 2008 and currently consists of ten Gastroenterology centres throughout Australia and New Zealand. The major objective of this Consortium is to progress knowledge and clinical practice in the field of IBD through the combination of both clinical and scientific research, thus improving patient outcomes across the Australian and New Zealand populations.
The main goals pursued by the Consortium in order to achieve its objectives are:
- A strong, collaborative IBD clinical and scientific network;
- A higher profile for IBD within the wider community and within the NHMRC;
- To establish and maintain a robust clinical IBD database with prospectively collected data on agreed fields; a universal tracking system for patient assessment, management and treatment, including the use of Biologics;
- To generate meaningful outcomes and safety data on our IBD population;
- To regularly benchmark and collaborate with European and North American colleagues.
- To study the genetics of IBD within the Australasian environment, including environmental factors that may influence disease development and natural history.
Under the auspices of the Australian and New Zealand IBD Consortium, the following Australian IBD centres have contributed to the International IBD Genetics Consortium studies:
Brisbane, Queensland, Australia
A/Prof Graham Radford-Smith
The Brisbane Inflammatory Bowel Disease Research Group consists of clinicians and scientists from the Royal Brisbane and Women's Hospital and the Queensland Institute of Medical Research (QIMR). Studies involve a specialist-based cohort of patients managed at the Royal Brisbane and Women's Hospital, a population-based cohort of patients from the North Brisbane community (total population 732,000), and non-IBD controls drawn from the same population.
QIMR, being the central hub for the ANZIBDC, has taken a lead role in the development of the ANZIBDC and continues to play a major role in the management of data and samples for the consortium.
Brisbane, Queensland, Australia
Prof Tim Florin
The Mater Health Services' IBD comprises a hospital-based IBD cohort in Brisbane. The principal investigators from this group are Prof Tim Florin, Dr Marianne Mortimore and Associate Professor Michael McGuckin.
- Prof Tim Florin: firstname.lastname@example.org
- Dr Marianne Mortimore: Marianne.email@example.com
- A/Prof Mike McGuckin: firstname.lastname@example.org
Fremantle, Western Australia
Prof Ian Lawrance
The Centre for Inflammatory Bowel Diseases, Fremantle Hospital is a specialist centre that currently manages over 1000 IBD patients. The principal investigator is Prof Ian C Lawrance from the School of Medicine and Pharmacology, University of Western Australia.
South Adelaide, South Australia
A/Prof Peter Bampton
The Southern Adelaide IBD Service is based in the southern suburbs of Adelaide and drains country patients from the southern aspect of South Australia, representing a population of approximately 400,000. The principal investigator from this group is A/Prof Peter Bampton, from the Department of Gastroenterology and Hepatology, Flinders Medical Centre.
- A/Prof Peter Bampton: email@example.com
Adelaide, South Australia
A/Prof Jane Andrews
The Royal Adelaide Hospital (RAH) IBD Service is based centrally in the city of Adelaide. The Service caters directly for a population of ~600,000 locally and many more by referral in from rural and regional South Australia. We currently care for over 500 IBD patients. Our unit has a particular interest in clinical care models, optimising the use of standard care, psychological and social issues in IBD and outreach care to IBD patients in remote locations. A/Prof Jane Andrews is the Head of the Service with Dr David Hetzel playing an active role in coordinating the unit's sponsored clinical trials. The unit is within the Department of Gastroenterology & Hepatology and linked also to the School of Medicine at the University of Adelaide.
Townsville, Queensland, Australia
Dr Gillian Mahy (Director of Medicine, Townsville Hospital, Queensland)
The Townsville Hospital IBD Service is based in regional North Queensland and covers an urban and rural population of some 250,000 with an additional rural and remote population draining from central and central north Queensland and Torres Strait Islands. The principal investigator is Dr Gillian Mahy assisted by research nurse Sharon Cooke. The unit resides within the Department of Gastroenterology and Hepatology and is linked with the School of Medicine, James Cook University.
- Dr Gillian Mahy: Gillian_Mahy@health.qld.gov.au
The Canterbury IBD Cohort is a population-based IBD cohort comprising 92% of IBD patients (1420) from the Canterbury region of New Zealnad (population ~500,000). The principal investigators from this group are A/Prof Richard Gearry, Dr Rebecca Roberts and Clinical Professor Murray Barclay from the Department of Medicine, University of Otago, Christchurch.